trending Market Intelligence /marketintelligence/en/news-insights/trending/2hjme2td3bhzs5i8mzt8hq2 content esgSubNav
In This List

Europe paves way for early stage Alzheimer's drugs

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Europe paves way for early stage Alzheimer's drugs

The European Medicines Agency has adopted a revised guideline on clinical studies for medicines that target Alzheimer's disease.

The new guidance aims to encourage the testing of new drugs before the disease's symptoms start appearing, as well as the potential use of biomarkers.

The guidance is expected to facilitate developing medicines to both prevent and treat the condition.

Alzheimer's is the most common type of dementia, which is characterized by the progressive loss of memory and other cognitive functions. Currently available Alzheimer's drugs can only treat its symptoms.

The EMA said, citing the World Health Organization, said 35.6 million people worldwide have dementia, and this number is expected to double by 2030. The disease affects more than 5 million people in the EU.